Market Trends of Mexico Nuclear Imaging Industry
Cardiology Segment is Expected to Witness a Steady Growth Over the Forecast Period
- There has been an increasing burden of cardiac diseases in Mexico, one of the significant factors fueling the market growth. Atherosclerotic cardiovascular disease (ASCVD), a buildup of fats, cholesterol, and other substances inside and on their walls, can narrow the arteries and obstruct blood flow.
- As per the data from the American Heart Association 2022, in Mexico, 56.1% of adults have high levels of low-density lipoprotein-cholesterol (LDL-C), or bad cholesterol, which is thought to be the primary risk factor for cardiovascular disease. In June 2022, with financing from Novartis, the American Heart Association (AHA) implemented a new science program in Mexico to enhance care for patients with ASCVD, often known as atherosclerosis. With such an initiative, cardiology care in the country will increase in prevention and treatment, ultimately boosting the demand for nuclear imaging equipment, as diagnosis is an integral part of cardiac care.
- Additionally, Mexico has several cardiology-related associations that work to improve cardiac care. For instance, the Mexican Society of Cardiology is dedicated to creating awareness about the risk factors associated with cardiac diseases and the treatments for heart failure. With such awareness, the general population can understand the importance of diagnostic imaging in cardiovascular diseases, ultimately increasing the number of people going for diagnostic imaging procedures in the country.
- Additionally, smoking is one of the leading risk factors for cardiovascular diseases. As per the World Population Review Report 2022, around 13.9% of the Mexican population smokes tobacco. This considerable number of smokers in the country also adds to the overall burden of cardiovascular diseases. Therefore, owing to the abovementioned factors, the segment is expected to witness steady growth in Mexico's nuclear imaging market.
Understand The Key Trends Shaping This Market
Download PDF
PET Radioisotopes Segment is Expected to Witness a Considerable Growth Over the Forecast Period
- Positron emission tomography (PET) scans use small amounts of radioactive materials called radioactive substances or radiopharmaceuticals, a special camera, and a computer to evaluate organ and tissue function. PET is a noninvasive nuclear imaging modality that is used, amongst many indications, for diagnosis, staging, and treatment monitoring of cancer. PET imaging is performed by administering, usually intravenously, a positron-tagged radiopharmaceutical to a patient. Most PET scans are performed using fluorodeoxyglucose, the gold standard of PET radiopharmaceuticals.
- The increasing prevalence of diseases requiring PET scans and the high burden of underlying conditions such as hypertension and dyslipidemia triggering chronic diseases are the major drivers for the segment. For instance, according to the report published by the Ministry of Health in June 2022, one in four Mexicans suffer from high blood pressure, and around 46.0% are unaware of it.
- Similarly, according to the National Institute of Statistics and Geography (Spanish: Instituto Nacional de Estadística y Geografía (INEGI)) published in 2022, 30.0 million Mexicans suffer from high blood pressure, representing about 24.9% and 26.1% of the male and female population, respectively. High blood pressure and dyslipidemia are critical risk factors for cardiovascular disorders and mortality.
- Thus, the increasing burden of these underlying conditions is expected to increase the prevalence of cardiovascular diseases. Since PET scans are mostly preferred for the detection of cardiovascular diseases, the increasing burden of cardiovascular diseases is anticipated to impact the segment growth positively.
